Process for preparing variant of
View Patent ↗A variant of Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form of SpaA (ΔSpaA) in which a portion of SpaA protein is deleted for protection from Erysipelothrix rhusiopathiae infection and a process for preparing the same are provided. Introduction of amino acid substitution at a specific site in the amino acid sequence of SpaA or ΔSpaA protein provides a variant of SpaA or ΔSpaA protein which is immunogenic and is expressed in E. coli as inclusion bodies. The variant of SpaA or ΔSpaA protein of the present invention may easily be recovered and purified since it is expressed in E. coli as inclusion bodies.
1. An isolated variant of an Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form thereof (known as ΔSpaA protein),
wherein the SpaA protein comprises the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:7, and the ΔSpaA protein is a shortened form of the SpaA protein in which the C-terminal 206 amino acid residues of the SpaA protein comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:7 are deleted,
wherein said variant is immunogenic, and expressed in E. coli as inclusion bodies, and is selected from the group consisting of:
(1) the SpaA protein comprising the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of arginine to glycine at the residue corresponding to residue position 531 of SEQ ID NO:2;
(2) the SpaA protein comprising the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2;
(3) the ΔSpaA protein with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2;
(4) the ΔSpaA protein with the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 69 of SEQ ID NO:2, the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 154 of SEQ ID NO:2, and the amino acid substitution of isoleucine to threonine at the residue corresponding to residue position 203 of SEQ ID NO:2; and
(5) the ΔSpaA protein with the amino acid substitution of aspartic acid to glycine at the residue corresponding to residue position 278 of SEQ ID NO:2.
2. A composition comprising as an active ingredient an isolated variant of an Erysipelothrix rhusiopathiae surface protective antigen SpaA protein or of a shortened form thereof (known as ΔSpaA protein),
wherein the SpaA protein comprises the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:7, and the ΔSpaA protein is a shortened form of the SpaA protein, in which the C-terminal 206 amino acid residues of the SpaA protein comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:7 are deleted,
wherein said variant is immunogenic, and expressed in E. coli as inclusion bodies, and is selected from the group consisting of:
(1) the SpaA protein comprising the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of arginine to glycine at the residue corresponding to residue position 531 of SEQ ID NO:2;
(2) the SpaA protein comprising the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2;
(3) the ΔSpaA protein with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2;
(4) the ΔSpaA protein with the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 69 of SEQ ID NO:2, the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 154 of SEQ ID NO:2, and the amino acid substitution of isoleucine to threonine at the residue corresponding to residue position 203 of SEQ ID NO:2; and
(5) the ΔSpaA protein with the amino acid substitution of aspartic acid to glycine at the residue corresponding to residue position 278 of SEQ ID NO:2.
3. A method for immunizing against infection with Erysipelothrix rhusiopathiae , comprising administering the variant of claim 1 to an animal in need of immunization.
4. The isolated variant of claim 1 , wherein the SpaA protein comprises the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of arginine to glycine at the residue corresponding to residue position 531 of SEQ ID NO:2.
5. The isolated variant of claim 1 , wherein the SpaA protein comprises the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2.
6. The isolated variant of claim 1 , which is the ΔSpaA protein with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2.
7. The isolated variant of claim 1 , which is the ΔSpaA protein with the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 69 of SEQ ID NO:2, the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 154 of SEQ ID NO:2, and the amino acid substitution of isoleucine to threonine at the residue corresponding to residue position 203 of SEQ ID NO:2.
8. The isolated variant of claim 1 , which is the ΔSpaA protein with the amino acid substitution of aspartic acid to glycine at the residue corresponding to residue position 278 of SEQ ID NO:2.
9. The composition of claim 2 , wherein the SpaA protein comprises the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of arginine to glycine at the residue corresponding to residue position 531 of SEQ ID NO:2.
10. The composition of claim 2 , wherein the SpaA protein comprises the amino acid sequence encoded by SEQ ID NO:7 with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2.
11. The composition of claim 2 , which is the ΔSpaA protein with the amino acid substitution of histidine to glutamine at the residue corresponding to residue position 214 of SEQ ID NO:2 and the amino acid substitution of methionine to threonine at the residue corresponding to residue position 253 of SEQ ID NO:2.
12. The composition of claim 2 , which is the ΔSpaA protein with the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 69 of SEQ ID NO:2, the amino acid substitution of glutamic acid to glycine at the residue corresponding to residue position 154 of SEQ ID NO:2, and the amino acid substitution of isoleucine to threonine at the residue corresponding to residue position 203 of SEQ ID NO:2.
13. The composition of claim 2 , which is the ΔSpaA protein with the amino acid substitution of aspartic acid to glycine at the residue corresponding to residue position 278 of SEQ ID NO:2.